View 32 reports from 10 analysts offering long term price targets
for Dr. Reddy's Laboratories Ltd..
Dr. Reddy's Laboratories Ltd. has an average target of 5727.22. The consensus estimate
represents an upside of 2.10%
from the last price of 5609.35.
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
All Recent
Upside
Buy
Sell
Recent Upgrades
Recent Downgrades
IPO
Sector Updates
Most Recent
Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
DRReddy’s consolidated revenue increased by 7% QoQ to INR 67,579 Mn (+35% YoY ). The company reported a YoY revenue growth, driven increase in North America generics sales, The North America generics revenue stood at USD 390 Mn. The growth in this region was mainly driven by growth in gRevlimid sales.
Dr. Reddy’s (DRL) delivered a strong beat in EBITDA and profit, driven by incremental sales from its base product portfolio and gRevlimid in the US. gRevlimid continues to lift overall margins; however, additional sales from products that are in shortage in the US improved base business margins in Q1FY24.
DRReddy’s saw a sequential drop in revenue to INR 63,152 Mn. Global generics, reported a revenue of INR 54,257 Mn, declined by 8% on a QoQ. However, the company witnessed YoY growth of 23.4%, driven by revenue growth in North America, Europe and India, partially offset by a decline of revenues in the emerging markets.
Company Outlook & Guidance: Q4FY22 results were week. However, we believe DRRD's strategy of in investing various businesses may provide growth in the long term.
Dr. Reddy’s Laboratories’ (DRL) Q3FY23 reported performance exceeded our and consensus estimates, largely driven by higher-than-estimated sales of Revlimid in Q3FY23. This resulted in 27.3% YoY growth in revenue to Rs67.7bn (I-Sec: Rs58.6bn).
